THIRUCHY: A 30-year-old man suffering from progressive vision loss for nearly a decade due to an eye injury recently regained ...

Hopkins engineer Vicky Nguyen has spent 15 years studying how glaucoma progresses to figure out how to preserve patients' ...

The bio-interventional platform is for uveoscleral outflow enhancement in open-angle glaucoma patients undergoing combined ...

A combination of low blood pressure and high intraocular pressure can predict RNFL thinning in moderate-to-severe glaucoma.

Eyenovia (EYEN), has entered into a non-binding letter of intent contemplating a potential reverse merger transaction with Betaliq, a clinical ...

The proposed merger would create a new ophthalmic company that combines two FDA-approved technologies: Betaliq’s EyeSol ® water-free drug delivery technology for use in glaucoma, and Eyenovia’s ...

A recent study has raised concerns about a widely used blood pressure medication called Calcium Channel Blockers (CCBs).

Glucagon-like peptide 1 receptor agonists appear to reduce the risk of age-related macular degeneration and primary open-angle glaucoma.

Pursuant to the Transaction documents, Iridex and Novel will jointly pursue growth initiatives which may result, at Novel’s election, in the issuance of an additional $10 million in aggregate ...

Glaucoma, a chronic eye disease, gradually damages the optic nerve, without showing any symptoms, but slowly leading to ...

Minimally invasive glaucoma surgeries offer an alternative to glaucoma drops, which, in some cases, do not adequately lower IOP and show poor compliance.